Transcutaneous bilirubin measurement: The comparison of the reliability of transcutaneous bilirubin measurement in comparison to a measurement of plasma.

Transcutaneous bilirubin measurement: Plasma versus transcutaneous.

Status

Recruiting

Phases

Unknown

Study type

Interventional

Source

NL-OMON

Registry ID

NL-OMON20391

Enrollment

Registered

2011-10-11

Start date

2011-11-01

Completion date

Unknown

Last updated

2024-02-28

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

neonaten die icterisch zien en geprikt worden op hyperbilirubinemie. icteric neonates who will be pinned on hyperbilirubinaemia.

Interventions

Measurement of bilirubin from serum, followed by transcutaneous measurements.

Eligibility

Inclusion criteria

Inclusion criteria: Neonates between 32-42 weeks gestation in which we want to determine a bilirubin.

Exclusion criteria

Exclusion criteria: 1. Neonates < 32 weeks of gestation; 2. Neonates with blood type antagonism; 3. Measurement of bilirubin < than 24 hours postpartum; 4. No informed consent.

Design outcomes

Primary

Measure	Time frame
Bilirubine levels of the two transcutaneous devices en the measurement from the serum.	—

Secondary

Measure	Time frame
Comparing of the bilirubine levels from the different devices and their sensitivity en specificity.	—

Contacts

Public ContactJudith Demmers

Omloop 68

jdemmers@amphia.nl+31 (0)76 5951575

Outcome results

None listed

Source: NL-OMON (via WHO ICTRP)